2017-02-005 - CANINHIB - Combination use of uric acid in stroke treated with rescue mechanical thrombectomy (CUAT)
Contacts
LT
Acronim & Gínjol codes
CANINHIB
2017-02-005
Main technology offer
We discovered several ligands which are the first, non-peptidic, small compounds that strongly and selectively inhibit dephosphorylation of the transcription factors NFATc by CN and thus NFATc signaling, T cell activation and the immune response
Ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Market Data
To identify functional non-peptide compounds that inhibit the activation of the immune response and/or tumour progression by inhibiting the signalling of calcineurin phosphatase on NFATc transcription factors, unlike the current immunosuppressive drugs cyclosporine and Tacrolimus (FK506) that inhibit the phosphatase activity of calcineurin on all its substrates.
0
0
0
Perform the PoC in order to build a strong TPP (Year 1) to license out the asset, and drafting a comprehensive regulatory strategy to maximize existing resources. In order to license out the asset thus, we would expect return of investment from this year (Year 8) as an upfront payment, then as a milestone at the end of Phase III Clinical trial (Year 10) and 3% of royalties in net sales from year 11.
Funding
Funding
Technology Status
To identify functional non-peptide compounds that inhibit the activation of the immune response and/or tumour progression by inhibiting the signalling of calcineurin phosphatase on NFATc transcription factors, unlike the current immunosuppressive drugs cyclosporine and Tacrolimus (FK506) that inhibit the phosphatase activity of calcineurin on all its substrates.
Additional information
Patents: EP3108883A1 - Dec 28th, 2016 - Status: Granted - URL: https://patents.google.com/patent/EP3108883A1/nl
We discovered several ligands, which are the first, non-peptidic, small compounds that strongly and selectively inhibit dephosphorylation of the transcription factors NFATc by CN and thus NFATc signaling, T cell activation and the immune response . Lesser side effects than current drugs are expected. They could improve patient quality of life and reduce health care costs. Oral administration is feasible and no cytotoxicity has been observed.